ArticleInternational ophthalmology2020
Complications of accelerated corneal collagen cross-linking: review of 2025 eyes.
Article in International ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Outcomes of Collagen Crosslinking in Patients with Keratoconus and Co-Existent Limbal Stem Cell Deficiency.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Management of corneal melting after collagen cross-linking for keratoconus: a case report and a review of the literature.BMC ophthalmology · 2024Review
- [Current aspects of vernal and atopic keratoconjunctivitis].Die Ophthalmologie · 2024Review
- Corneal collagen cross-linking in patients with keratoconus from the Dresden protocol to customized solutions: theoretical basis.International journal of ophthalmology · 2024Review
- A review of the epithelial and stromal effects of corneal collagen crosslinking.The ocular surface · 2023Review
- Safety and Efficacy of Corneal Cross-Linking in Patients Affected by Keratoconus: Long-Term Results.Medical sciences (Basel, Switzerland) · 2023Article
- Evaluation of a Post-Operative Therapy Protocol after Epithelium-Off Corneal Cross-Linking in Patients Affected by Keratoconus.Journal of clinical medicine · 2022Article
- Retrospective Analysis of Sterile Corneal Infiltrates in Patients with Keratoconus after Cross-Linking Procedure.Journal of clinical medicine · 2022Article
- Acute Anterior Uveitis with HLA-B27 Positivity after Corneal Cross-Linking with Previous Intrastromal Corneal Ring Segment.Case reports in ophthalmological medicine · 2022Article
- Article
- Chemically-Boosted Corneal Cross-Linking for the Treatment of Keratoconus through a Riboflavin 0.25% Optimized Solution with High Superoxide Anion Release.Journal of clinical medicine · 2021Article
- Unusual ectasia following corneal cross-linking in a patient with keratoconus.Romanian journal of ophthalmologyReview
- A Novel Oxygen Chamber for Corneal Cross-Linking in a High-Oxygen Environment: A Pilot Study and Clinical Outcomes.Journal of current ophthalmologyArticle
- Keratometric Outcomes after Simultaneous versus Sequential Intracorneal Ring Segment Implantation with Femtosecond Laser and Corneal Collagen Crosslinking in Egyptian Patients with Keratoconus and Ectasia.Journal of microscopy and ultrastructureArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the early- and late-stage complications of accelerated cross-linking (A-CXL) in a large case series and investigate the relationship of A-CXL complications with ocular and systemic conditions accompanying keratoconus.
methodsRetrospectively, records of 2025 eyes of 1184 patients diagnosed with keratoconus between March 2013 and 2020 who underwent A-CXL (18 mW/cm
resultsThe mean age of patients was 26.16 ± 6.05 (range 18-42), and the mean follow-up time was 3.40 ± 1.63 years (range 1-8 years). Vernal keratoconjunctivitis (3.7%) was the most common disease accompanying keratoconus. Less frequently, systemic allergic diseases (2.9%) and Down syndrome (2.3%) were observed. The most common complication in the early postoperative period was haze formation (9.1%), while failure of the treatment (4.2%) occurred in the late period. Other common complications were loss of two or more Snellen lines (2.4%) and delayed epithelial healing (1.8%). There was a significant relationship between vernal keratoconjunctivitis and delayed epithelial healing (p = 0.011). Statistically significant relationships were found between Down syndrome and haze formation (p < 0.001) and sterile infiltrate formation (p = 0.041).
conclusionAlthough A-CXL complication rates are low, vernal keratoconjunctivitis following A-CXL might increase the risk of delayed epithelial healing, and similarly corneal haze and sterile infiltrates might be observed more frequently in patients with Down syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.